We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

HospiMedica

Download Mobile App
Recent News AI Critical Care Surgical Techniques Patient Care Health IT Point of Care Business Focus

Hospital Antibiotic Policies Improve Prescription Practices

By HospiMedica International staff writers
Posted on 21 Feb 2017
An updated review of studies identifies effective guidelines and policies to reduce unnecessary use of antibiotics in hospitals.

Researchers at the University of Dundee, University College London, and other institutions searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, and Embase for studies examining the effectiveness and safety of interventions designed to improve antibiotic prescribing to hospital inpatients, and to investigate the effect of different intervention functions. In all, the researchers found 221 studies from the United States, Europe, Asia, South America, and Australia.

The researchers found that interventions broadly fell into two categories; 'restrictive' techniques applied rules to make physicians prescribe properly, whilst 'enabling' techniques provided advice or feedback to help physicians make more informed prescribing decisions. In both cases, the aim of the intervention was to increase the number of appropriate prescribing decisions so that patients who were unlikely to benefit from antibiotics did not get them, whilst they were still used for patients who stood to benefit from them.

The results showed that interventions that included enabling or restrictive techniques were consistently more effective than interventions that relied on simple education alone. Moreover, a synergistic effect existed, with enabling techniques increasing the effectiveness of restrictive techniques. In addition, the interventions shortened duration of antibiotic use from 11 to 9 days per patient, and reduced hospital stay from an average of 13 days to 12 per patient. The review was published on February 9, 2017, in The Cochrane Library.

“We do not need more studies to answer the question of whether these interventions reduce unnecessary antibiotic use, but we do need more research to understand why the most effective behavior change techniques are not more widely adopted within hospital settings,” concluded lead author Peter Davey, PhD, of the UD department of population health sciences. “Appropriate antibiotic use in hospitals should ensure effective treatment of patients with infection, and reduce unnecessary prescriptions.”

For the study, the researchers defined restriction as using rules to reduce the opportunity to engage in the target behavior, or increase the target behavior by reducing the opportunity to engage in competing behaviors. Enablement was defined as increasing the means and reducing the barriers in order to increase capability or opportunity.

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Gold Member
Handheld Blood Glucose Analyzer
STAT-Site
New
Monitor/Defibrillator
Zenix
New
Multi-Chamber Washer-Disinfector
WD 390

Channels

Critical Care

view channel
Image: The nasal spray is created using the ‘Nano-in-Micron’ technology platform. The micron-sized powder is inhaled and travels along the nose-to-brain pathway, bypassing the blood-brain barrier to deliver the drug directly to the brain (Photo courtesy of The University of Hong Kong

New Nasal Spray Enables Prehospital Neuroprotection in Ischemic Stroke

Ischemic stroke, caused by arterial occlusion in the brain, requires time‑critical intervention to limit neuronal loss. Many patients arrive outside the narrow window for thrombolysis or thrombectomy,... Read more

Surgical Techniques

view channel
Image: MUSA-3 is designed to assist surgeons during open super‑microsurgical procedures by downscaling and stabilizing hand movements (Photo courtesy of Microsure)

Robotic Microsurgery System Gains CE Mark for Clinical Use in Europe

Microsure (Eindhoven, The Netherlands) announced on May 7, 2026 that its MUSA-3 system received CE mark approval, enabling clinical use in Europe. The milestone marks the company’s transition from product... Read more